Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0VO0T
|
|||
| Former ID |
DNCL003479
|
|||
| Drug Name |
Delanzomib
|
|||
| Synonyms |
((R)-1-((2S,3R)-3-hydroxy-2-(6-phenylpicolinamido)butanamido)-3-methylbutan-2-yl)boronic acid; s1157; ZINC202536926; SB16695; SW219161-1; boronic acid, b-[(1r)-1-[[(2s,3r)-3-hydroxy-1-oxo-2-[[(6-phenyl-2-pyridinyl)carbonyl]amino]butyl]amino]-3-methylbutyl]-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Multiple myeloma [ICD-11: 2A83; ICD-10: C90; ICD-9: 203] | Phase 2 | [1] | |
| Company |
Cephalon
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C21H28BN3O5
|
|||
| Canonical SMILES |
B(C(CC(C)C)NC(=O)C(C(C)O)NC(=O)C1=CC=CC(=N1)C2=CC=CC=C2)(O)O
|
|||
| InChI |
1S/C21H28BN3O5/c1-13(2)12-18(22(29)30)24-21(28)19(14(3)26)25-20(27)17-11-7-10-16(23-17)15-8-5-4-6-9-15/h4-11,13-14,18-19,26,29-30H,12H2,1-3H3,(H,24,28)(H,25,27)/t14-,18+,19+/m1/s1
|
|||
| InChIKey |
SJFBTAPEPRWNKH-CCKFTAQKSA-N
|
|||
| CAS Number |
CAS 847499-27-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ChEBI ID |
CHEBI:141530
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Proteasome (PS) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.Curr Cancer Drug Targets. 2014;14(6):517-36. | |||
| REF 2 | Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE. Int Immunopharmacol. 2012 Jan;12(1):257-70. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.